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dopamine agonists (DAs) influence the production of these 
growth factors.  Methods: In panNET cells (BON-1 and QGP-1) 
and GEP-NETs, mRNA expression of IGF-related factors was 
measured by quantitative real-time PCR. Effects of the SSAs 
octreotide and pasireotide (PAS), the DA cabergoline (CAB), 
and the dopastatin BIM-23A760 (all 100 n M ) were evaluated 
at the IGF2 mRNA and protein level (by ELISA) and regarding 
IR-A bioactivity (by kinase receptor activation assay) in pan-
NET cells.  Results: panNET cells and GEP-NETs had compa-
rable expression profiles of IGF-related factors. Especially in 
BON-1 cells, IGF2 and IR-A were most highly expressed. PAS 
+ CAB inhibited IGF2 (–29.5 ± 4.9%, p < 0.01) and IGFBP3 
(–20.0 ± 4.0%, p < 0.01) mRNA expression in BON-1 cells. In 
BON-1 cells, IGF2 protein secretion was significantly inhibit-
ed with BIM-23A760 (–23.7 ± 3.8%). BON-1- but not QGP-1-
conditioned medium stimulated IR-A bioactivity. In BON-1 
cells, IR-A bioactivity was inhibited by BIM-23A760 and PAS 
+ CAB (–37.8 ± 2.1% and –30.9 ± 4.1%, respectively, p < 
0.0001).  Conclusions: (1) The BON-1 cell line is a representa-
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 Abstract 
 Background: Gastroenteropancreatic neuroendocrine tu-
mors (GEP-NETs) express insulin-like growth factor (IGF)-re-
lated factors [IGF1, IGF2; insulin receptor (IR)-A, IR-B; IGF-
binding protein (IGFBP) 1–3] as well as somatostatin (SSTRs) 
and dopamine D 2 receptors (D2Rs).  Objectives: To (1) com-
pare mRNA expression of IGF-related factors in human pan-
creatic NET (panNET) cell lines with that in human GEP-NETs 
to evaluate the usefulness of these cells as a model for study-
ing the IGF system in GEP-NETs, (2) determine whether pan-
NET cells produce growth factors that activate IR-A, and (3) 
investigate whether somatostatin analogs (SSAs) and/or
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tive model for studying the IGF system in GEP-NETs, (2) BON-
1 cells produce growth factors (IGF2) activating IR-A, and (3) 
combined SSTR and D2R targeting with PAS + CAB and BIM-
23A760 suppresses IGF2-induced IR-A activation. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 The insulin-like growth factor (IGF) system is consid-
ered to play an important role in gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs)  [1–3] . The IGF sys-
tem is involved in cell metabolism, growth, differentia-
tion, and survival  [4–6] . Known proteins that are part of 
this IGF system include IGF1 and IGF2, IGF receptor 1 
(IGF1R), IGF2R, insulin receptor (IR) isoforms A (IR-A) 
and B (IR-B), and IGF-binding proteins 1, 2, and 3 
(IGFBP1–3).
 The tumor-promoting role of IGF1, IGF2, and IGF1R 
in cancer has previously been explored  [7–9] . IGFs can 
also exert their effects after binding to IR-A and IR-B. 
IR-A has mainly mitogenic effects and IR-B is involved in 
metabolic activities  [7, 9] . We have recently shown that, 
compared to IGF1R and IR-B, IR-A was the most pre-
dominantly expressed receptor in GEP-NETs  [10] . In ad-
dition, we have shown that BON-1 pancreatic NET (pan-
NET) cells produce growth factors (IGF2) that stimulate 
IGF1R in an autocrine/paracrine manner  [11] . To the 
best of our knowledge, the functional role of IR-A has not 
been studied in this respect.
 GEP-NET cells also express somatostatin receptors 
(SSTRs) and dopamine type 2 receptors (D2Rs), which 
are known to inhibit the secretion of many factors/hor-
mones  [12–14] . SSTRs and D2Rs are highly, but variably, 
expressed in most GEP-NETs, and their expression may 
depend on the stage of tumor dedifferentiation  [12–14] . 
Of the SSTRs, SSTR2 is the most abundantly expressed 
subtype. Somatostatin analogs (SSAs) such as octreotide 
(OCT) and lanreotide, which act primarily via SSTR2, are 
used in the treatment of GEP-NETs and were previously 
shown to control symptoms related to the overproduc-
tion of hormones and bioactive substances, and more re-
cently to control tumor progression as well  [15, 16] .
 In theory, targeting SSTRs and/or D2Rs could result in 
lowering of the production of factors that interact with 
IR-A. Heterodimerization of SSTRs and D2Rs can result 
in receptors with an enhanced functional activity  [17, 18] . 
As such, the combination of single-receptor ligands such 
as dopamine agonists (DAs) and SSAs, and also soma-
tostatin-dopamine (SS-DA) chimeric compounds, could 
have synergistic effects by targeting these coexpressed re-
ceptors in GEP-NETs. Beneficial effects of chimeric com-
pounds and multiligand SSAs were already shown in a 
subgroup of patients with NETs and growth hormone/
prolactin-secreting pituitary adenomas  [19–22] . In one 
study, antiproliferative effects were observed in the small 
intestinal NET (siNET) cell line KRJ-I after incubation 
with multiligand SSAs but not with SS-DA, because KRJ-
I cells lack D2R expression  [23] .
 To the best of our knowledge, there are no studies in 
GEP-NET cells in which the effect of targeting SSTRs and 
D2Rs on the production of IGF-related factors has been 
evaluated. The main aims of our study were: (1) to com-
pare the expression of the IGF system in human panNET 
cells (BON-1 and QGP-1) and a series of GEP-NET tis-
sues and to investigate in which aspect the human pan-
NET cell models reflect the human IGF system in GEP-
NETs; (2) to evaluate whether panNET cells produce 
growth factors that are able to activate IR-A, and (3) to 
investigate whether SSAs and/or DAs can influence the 
production of these growth factors.
 Materials and Methods 
 Cell Lines and Culture Conditions 
 For functional experiments, we used the human panNET cell 
lines BON-1 and QGP-1. The BON-1 cell line was established from 
a lymph node metastasis of a human functional panNET  [24] and 
was a kind gift of Dr. C.M. Townsend (The University of Texas Med-
ical Branch, Galveston, Tex., USA). The QGP-1 cell line, which was 
derived from a pancreatic islet cell carcinoma, was obtained from the 
Japanese Collection of Research Bioresources (JCRB) Cell Bank  [25] .
 In kinase receptor activation (KIRA) bioassays, we utilized the 
human embryonic kidney (HEK) cell line Flip-in TM -293 from
Invitrogen (Breda, The Netherlands), which was stably transfected 
with plasmids (pNTK-2) containing a cDNA insert of the human 
IR-A gene, using Fugene ® transfection reagents according to man-
ufacturer’s protocol  [26] . The IR-A plasmid was kindly provided 
by Axel Ullrich (Martinsried, Germany).
 Cell lines were routinely cultured in 75-cm 2 cell culture flasks 
from Corning (Amsterdam, The Netherlands). BON-1 cells were 
cultured in culture medium consisting of a 1: 1 mixture of DMEM 
and F-12K medium, supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin, 0.5 mg/l Fungizone, and 2 m M  L -glu-
tamine. QGP-1 cells were cultured in RPMI 1640 culture medium 
enriched with 10% FBS and 100 U/ml penicillin. HEK IR-A cells 
were grown in DMEM containing 10% FBS, 100 U/ml penicillin, 
100 μg/l streptomycin, and 500 μg/ml geneticin from Invitrogen.
 The cell lines were passaged weekly by trypsinization with tryp-
sin/EDTA (0.05%/0.53 m M ) and resuspension in medium. Trypan 
blue staining was used to assess cell viability, which always exceed-
ed 95%. Before plating, cells were counted microscopically in a 
standard hemocytometer. Periodically, cells were confirmed as 
free of  Mycoplasma . The cell culture conditions in the incubator 
were kept at a humidified atmosphere of 5% CO 2 at 37  °  C.
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 Cell Experiments for mRNA Expression and IR-A Bioactivity 
(KIRA Assay) 
 For all mRNA expression and IR-A bioactivity experiments, 
both panNET cell lines were seeded at a density of 100,000 cells/
well in 12-multiwell culture plates (Corning). After 48 and 72 h, 
the media were refreshed with serum-free medium.
 In order to test whether growth factors produced by panNET 
cells could influence the tyrosine kinase activity of IR-A, 72-hour 
conditioned medium of BON-1 cells and QGP-1 cells was collect-
ed. Since QGP-1-conditioned medium showed no tyrosine kinase 
IR-A bioactivity, we did not further evaluate the effects of SSAs/
DAs on this cell line. Therefore, all further experiments were per-
formed with BON-1 cells only.
 BON-1 cells were incubated for 72 h without or with SSAs and/
or DAs at a concentration of 100 n M . After 72 h of incubation, su-
pernatant of the cells was collected, stored at –20  °  C, and later used 
for IR-A bioassays. The same control and treated BON-1 cells were 
used for total RNA isolation. The samples were stored at –20   °   C 
until analysis. The ability of BON-1-secreted factors to stimulate 
IR-A phosphorylation was measured using an in-house IR-A 
KIRA assay according to a previously published method  [27] . Bio-
activity was expressed relative to a standard curve of insulin. The 
treatment groups were tested in quadruplicate.
 Test Substances 
 Regarding SSAs, we tested OCT (Novartis Pharma AG, Basel, 
Switzerland) and the multi-receptor-binding SSA pasireotide (PAS), 
also known as SOM230  [28] . PAS was a gift from Novartis. The DA 
used was cabergoline (CAB; Pharmacia-Pfizer, New York, N.Y., 
USA). The SS-DA chimeric compound BIM-23A760 was provided 
by Biomeasure Inc./IPSEN (Milford, Mass., USA). Cells were treat-
ed with either single drugs or with drug combinations, namely OCT 
+ CAB and PAS + CAB. The SSTR and D2R binding affinities of all 
compounds are listed in online supplementary table 1 (for all online 
suppl. material, see www.karger.com/doi/10.1159/000444280)  [22, 
28–33] . Stock solutions of SSAs were prepared in 0.01  M acetic acid 
and 0.1% bovine serum albumin. CAB was dissolved in 70% ethanol. 
All stock solutions were aliquoted at concentrations of 10 –4  M and 
stored at –20  °  C. For each experiment, fresh working solutions were 
diluted in serum-free medium.
 GEP-NET Tissues 
 The diagnosis of GEP-NET was based on both clinical param-
eters and histology. Samples of GEP-NETs were immediately fro-
zen after surgery in liquid nitrogen and stored at –80  °  C until fur-
ther analysis. Tissues obtained from the Erasmus Medical Center 
(MC) Tissue Bank were stored according to a standardized proto-
col  [34] . Approval from the Medical Ethics Committee of the Eras-
mus MC, as well as informed consent to use the tumor tissues for 
research purposes, was obtained.
 Quantitative Real-Time PCR 
 Total RNA of panNET cells and GEP-NET samples was iso-
lated to determine mRNA expression of the IGF-related factors 
according to the manufacturer’s protocol with a High Pure Isola-
tion KIT (Roche Diagnostics, The Netherlands).
 Poly A + mRNA isolation for detection of SSTR and D2R mRNA 
in panNET cells was performed according to a previously used 
method  [35] . The synthesis of cDNA and quantitative real-time 
PCR was conducted as previously described  [36] .
 The used primer probe sets of all IGF-related factors, including 
their sequences and concentrations, have been previously pub-
lished  [10] . Relative mRNA expression of IGF-related factors was 
calculated using the comparative threshold method after efficiency 
correction of target and reference gene (HPRT) transcripts  [37, 
38] . The tested compounds did not significantly change the ex-
pression of HPRT after 72 h of incubation (data not shown).
 IGF2 Protein Assay 
 To test whether inhibition of IR-A activation could be clarified 
by modulation of IGF2 secretion, we used a ‘two-step’ sandwich-
type immunoassay with a Non-Extraction IGF-II Enzyme-Linked 
Immunosorbent Assay Kit (DSL Germany GMBH-Benelux,
Assendelft, The Netherlands). The assay was performed according 
to the protocol supplied by the manufacturer. The intra- and in-
terassay coefficients of variability were 5.2 and 6.9%, respectively.
 IGF2 Immunohistochemistry 
 Expression of the IGF2 protein in GEP-NET tissues was mea-
sured by immunohistochemistry (IHC) using a polyclonal goat
antibody (1: 500; Santa Cruz Biotechnology, Dallas, Tex., USA) as 
previously described  [36] . The immunoreactivity of IGF2-stained 
GEP-NET tissues was interpreted in a semiquantitative manner 
and expressed as an immunoreactivity score (IRS) between 0 and 
6  [39] . The IGF2 staining and IRS counting procedure were done 
by 2 independent researchers, and any discrepancy was resolved 
by consensus review.
 Statistical Analysis 
 For statistical analysis, GraphPad Prism ® version 6.04 (Graph-
Pad Software, San Diego, Calif., USA) was used. Comparative sta-
tistical evaluations between groups were accomplished with un-
paired t tests and one-way ANOVA followed by Tukey’s tests for 
multiple post hoc comparisons. Correlation analysis was per-
formed using Spearman’s rank correlation tests. Each drug condi-
tion of an experiment was tested in quadruplicate, with the excep-
tion of the IGF2 ELISA, which was done in triplicate. All experi-
ments were carried out at least 2 times and gave comparable results. 
Outliers were excluded by Grubbs’ test with the GraphPad Quick-
Calcs outlier calculator. Data are reported as means ± SEM. In all 
analyses, a two-sided p value <0.05 ( *  p < 0.05,  * *  p < 0.01) was 
considered statistically significant.
 Results 
 Levels of mRNA Expression of SSTRs and D2Rs in 
panNET Cells 
 Figure 1 a shows mRNA levels of SSTRs and D2Rs in 
BON-1 cells. The SSTR subtypes were expressed in the 
following order: SSTR5 > SSTR1 > SSTR2 > SSTR3 (0.57 
± 0.093, 0.47 ± 0.058, 0.081 ± 0.011, and 0.036 ± 0.0065). 
The D2R mRNA expression level was 0.27 ± 0.011. Of all 
receptors, SSTR5 was expressed most highly.
 In QGP-1 cells, the order of expression was the same 
as in BON-1 cells, but the expression of SSTR3 was not 
detectable (SSTR5: 0.05 ± 0.02; SSTR1: 0.038 ± 0.022; 
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SSTR2: 0.005 ± 0; SSTR3: not detectable). D2R is the 
most highly expressed receptor in QGP-1 cells, and is 
expressed at the same level as in BON-1 cells (0.16 ± 0.08) 
( fig. 1 b).
 mRNA Expression of IGF-Related Factors in
panNET Cells 
 mRNA expression levels of the IGF-related factors 
were measured in BON-1 ( fig.  1 c) and QGP-1 cells 
( fig. 1 d). The results are expressed as relative expression 
(normalized to HPRT). In BON-1 cells, IGF2 was ex-
pressed at the highest level (292.8 ± 34.60). BON-1 cells 
expressed statistically significantly higher mRNA levels 
of IGF2 than of IGF1 (p < 0.01). Of the IGF-related recep-
tors, IR-A had the highest mRNA expression level (0.27 
± 0.016). IR-A was significantly more highly expressed 
(14.3-fold) than IR-B (0.27 ± 0.016 vs. 0.019 ± 0.0016, p < 
0.01). In addition, IR-A was expressed at a higher level 
(1.2-fold) than IGF1R (0.27 ± 0.016 vs. 0.22 ± 0.0093, p < 
0.05). No statistically significant difference in mRNA ex-
pression levels was observed between IR-A and IGF2R 
(0.27 ± 0.016 vs. 0.24 ± 0.019, p > 0.05) or between IGF1R 
and IGF2R (0.22 ± 0.0093 vs. 0.24 ± 0.019, p > 0.05). With 
respect to IGFBPs, IGFBP2 (0.76 ± 0.034) was expressed 
at the highest level, followed by IGFBP3 (0.35 ± 0.023) 
and IGFBP1 (0.023 ± 0.0019).
 IGF-related factors were expressed in a relatively com-
parable pattern in QGP-1 cells, but their expression levels 
were considerably lower than in BON-1 cells. panNET 
IGF2 (292.8 ± 34.60 vs. 0.26 ± 0.15, p = 0.01) and IR-A 
(0.27 ± 0.016 vs. 0.064 ± 0.005, p = 0.0003) were signifi-
cantly more highly expressed in BON-1 cells than in 
QGP-1 cells. In addition, in QGP-1 cells there was no de-
tectable expression of IGFBP1 and IGFBP3.
0
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 Fig. 1. mRNA expression profiles of SSTRs 
and D2R ( a ,  b ) and IGF-related factors
( c ,  d ) in BON-1 ( a ,  c ) and QGP-1 cells
( b ,  d ), expressed as relative expression nor-
malized to HPRT. For all samples: n = 2. 
ND = Not detectable. 
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 mRNA Expression of IGF-Related Factors in 
GEP-NET Tissues 
 The mRNA expression levels of IGF-related factors were 
investigated in primary human GEP-NETs originating 
from the small intestine (n = 18;  fig. 2 a: IGF-related recep-
tors,  fig.  2 c: IGF-related proteins) and pancreas (n = 7; 
 fig. 2 b: IGF-related receptors,  fig. 2 d: IGF-related proteins). 
Expression data on a subset of these GEP-NETs were previ-
ously reported  [10] . All genes were expressed in highly vari-
able amounts. Of the IGFs, IGF2 was most highly expressed 
(siNET: 3.60 ± 1.31; panNET: 1.05 ± 0.56). IGF2 was ex-
pressed at a higher level than IGF1 (siNET: 3.60 ± 1.31 vs. 
0.71 ± 0.20; panNET: 1.05 ± 0.56 vs. 0.35 ± 0.25). IR-A was 
the most prominently expressed IGF-related receptor in 
this series of GEP-NET tissues; it was expressed at a higher 
level than IR-B (siNET: 4.34 ± 0.69 vs. 1.50 ± 0.42; panNET: 
1.87 ± 0.41 vs. 0.47 ± 0.18) and IGF1R as well (siNET: 0.34 
± 0.11; panNET: 0.12 ± 0.06) ( fig. 2 a, b). Although the ex-
pression levels varied, overall siNETs and panNETs showed 
mRNA expression patterns of IGF-related factors compa-
rable to those of the panNET cell lines. Results of logarith-
mic gene expression levels are shown.
 Receptor Bioactivity after Stimulation with 
Serum-Free Conditioned BON-1 Cell Medium 
 Conditioned medium of BON-1 cells stimulated IR-A 
bioactivity, whereas control, unconditioned medium did 
not ( fig. 3 a). Conditioned medium of QGP-1 cells did not 
show any detectable bioactivity of IR-A (data not shown).
 In the IR-A KIRA assay, the strongest inhibition of 
BON-1 conditioned medium-induced IR-A bioactivity 
was observed after treatment for 72 h with the SS-DA
chimera BIM-23A760 (–37.8 ± 2.1%, p < 0.0001). Other 
compounds or combinations of compounds (all tested at 
100 n M ) that induced a statistically significant decrease
in conditioned medium-induced IR-A bioactivity were: 
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in siNETs ( a ,  c ; n = 18) and panNETs ( b ,  d ; 
n = 7), expressed as log relative expression 
normalized to HPRT. Horizontal bars rep-
resent means. 
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PAS + CAB (–30.9 ± 4.1%, p < 0.0001), OCT + CAB 
(–26.5 ± 2.1%, p < 0.01), CAB (–24.1 ± 3.4%, p < 0.05), 
and PAS (–19.4 ± 2.6%, p < 0.05). No statistically signifi-
cant differences in IR-A bioactivity were observed after 
treatment with OCT (–8.0 ± 6.1%). Data, expressed as 
percentage change from baseline of IR-A activation, are 
shown in  figure 3 b. None of the compounds had a direct 
effect on IR-A phosphorylation (data not shown), indi-
cating that the effects involved inhibition of the secretion 
of growth factors produced by BON-1 cells. Under the 
conditions that we used, concentrations of IGF2 between 
0.25 and 0.5 n M induced an IR-A activation comparable 
to that of BON-1 conditioned medium (data not shown).
 mRNA Levels of IGF-Related Factors after Treatment 
with SSAs and DAs 
 First, mRNA levels of IGF-related factors were mea-
sured after 6, 24, and 72 h of treatment. After 72 h, the 
mRNA data showed the most significant changes. 
Therefore, all experiments were accomplished at that 
time point. A significant decrease in IGF2 mRNA was 
observed after treatment with PAS + CAB (–29.5 ± 
4.9%, p < 0.01). The results are shown in  figure 4 . 
IGFBP3 expression as well was significantly decreased 
after treatment with PAS + CAB (–20.0 ± 4.0%, p < 0.01; 
data not shown). No other statistically significant ef-
fects on mRNA expression were found for the remain-
ing IGF-related factors. None of the other drugs or 
combinations were able to modulate mRNA expression 
levels.
 IGF2 ELISA 
 Total IGF2 protein levels were quantitatively mea-
sured in conditioned medium of BON-1 cells. A signifi-
cant decrease in IGF2 protein levels was observed after 72 
h of incubation with BIM-23A760 (–23.7 ± 3.8%). Inhib-
itory but statistically nonsignificant effects were observed 
with the other compounds (OCT: –12.5 ± 5.3%; CAB: 
–12.1 ± 4.8%; PAS + CAB: –9.8 ± 8.2%; PAS: –12.0 ± 3.3%; 
OCT + CAB: –5.7 ± 12.4%). The results are shown in  fig-
ure 5 .
10
0
Ch
an
ge
 in
 IG
F2
 m
RN
A 
ex
pr
es
si
on
 (%
)
–10
–20
–30
–40
–50
OC
T
PA
S
CA
B
OC
T +
 CA
B
PA
S +
 CA
B
BIM
-2
3A
76
0
**
0
IR
-A
 a
ct
iv
at
io
n 
(p
M
)
ch
an
ge
 fr
om
 b
as
el
in
e 
(%
)
–10
–20
–30
–40
–50
NS
Affinity
SSTR2
SSTR5
D2R
+
±
–
+
+
–
–
–
+
+
±
+
+
+
+
+
±
+
OC
T
PA
S
CA
B
OC
T +
 CA
B
PA
S +
 CA
B
BIM
-2
3A
76
0
**** **********
200
IR
-A
 a
ct
iv
at
io
n 
(p
M
) 150
100
50
CMUM
ND
0
****
a
b
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 Fig. 4. Change in mRNA expression of IGF2 after 72 h of treatment 
with single or combinations of compounds in BON-1 cells.  * *  p < 
0.01 vs. control. 
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 IGF2 Immunohistochemistry 
 IGF2 IHC was determined in 25 tissue samples of
siNET (n = 18) and panNET (n = 7) in order to examine 
IGF2 protein expression. Most of the tumors expressed a 
significant amount of IGF2 protein, although its expres-
sion was variable. The intensity and proportion of IGF2 
IHC staining were heterogeneous in most of the GEP-
NET tissues. In online supplementary table 2, the IGF2 
mRNA and protein expression levels of both siNETs and 
panNETs are listed. No significant correlation was ob-
served between IGF2 mRNA and IGF2 protein in siNETs 
(ρ = 0.17, p = 0.49) and panNETs (ρ = 0.44, p = 0.33), ex-
pressed as IGF2 IRS.  Figure 6 shows exemplary photomi-
crographs of staining of IGF2 in GEP-NET samples with 
an IRS of 2, 4, and 6, respectively. There was no statisti-
cally significant association between the proliferation 
marker Ki-67 and IGF2 IRS in siNETs (ρ = –0.09, p = 
0.79) and panNETs (ρ = 0.89, p = 0.11).
 Discussion 
 To the best of our knowledge, this is the first study hav-
ing gathered evidence that the human BON-1 cell line is 
a model that reflects in many respects the typical charac-
teristics of the IGF system in human GEP-NETs. We 
showed that especially IGF2 and IR-A were expressed at 
high levels in our series of GEP-NETs as well as in the 
BON-1 cell model. In addition, we demonstrated that 
SSAs and DAs modulate the secretion of growth factors 
(e.g. IGF2) produced by BON-1 cells that are capable of 
activating IR-A.
 We measured mRNA levels of IGF-related factors 
(IGF1, IGF2, IGF1R, IGF2R, IR-A, IR-B, and IGFBP1–3) 
in both panNET cell lines and GEP-NETs. In earlier pub-
lications, the expression of these genes has been studied 
in human NETs  [2, 10] . However, the quantitative ex-
pression of factors of the IGF system, and modulation of 
the expression of these growth factors (both at the mRNA 
and the protein level, during treatment with SSAs, DAs, 
or their combinations), have not been studied so far.
 Overall, BON-1 and QGP-1 cells displayed an expres-
sion pattern of IGF-related factors which was relatively 
comparable to that of GEP-NETs, both siNETs and
panNETs. However, BON-1 cells did not express detect-
able levels of IGF1, and QGP-1 cells did not express de-
tectable levels of IGF1, IGFBP1, and IGFBP3. In BON-1 
cells, IGF2 mRNA levels were expressed 1,000-fold more 
highly, and IR-A levels 5-fold more highly, than in
QGP-1 cells. The relatively low mRNA expression levels 
of IGF2 (and IR-A) in QGP-1 cells may explain the ab-
sence of effects of conditioned medium of QGP-1 on 
IR-A bioactivity. Therefore, the QGP-1 cell line appears 
not to be a suitable model for investigating whether SSAs 
and/or DAs can modulate the production of these growth 
factors. On the other hand, both cell lines are panNET cell 
lines, and the difference between the cell lines might re-
flect the heterogeneity of this tumor group.
 In both BON-1 and QGP-1 cells, we observed higher 
mRNA expression levels for SSTR1 than for SSTR2. The 
siNET cell line KRJ-I demonstrated equal mRNA expres-
sion levels for SSTR1 and SSTR2  [3] . In most studies 
where the quantitative mRNA expression levels of SSTRs 
were studied, SSTR2 was more highly expressed than 
SSTR1  [40–44] . In general, there is a predominant ex-
pression of SSTR1 and SSTR2 mRNA in NETs, with high-
ly variable mRNA expression levels  [40, 45] . We suggest 
that these differential findings again represent the hetero-
geneity of these tumors. No SSTR/D2R mRNA expres-
sion levels were determined in our series of GEP-NETs, 
since expression profiles of these receptors have already 
been extensively investigated  [40, 42] .
 For all experiments, we used the concentration of 100 
n M of OCT, PAS, CAB, and/or BIM-23A760. With this 
supraphysiological concentration, we expected to ob-
serve effects that could answer our primary research 
question, i.e. to investigate whether the different SSAs 
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and/or DAs used were able to activate SSTR subtypes and 
D2R resulting in a maximal biological response. At such 
a concentration, it is not fully possible to make statements 
about the specific involvement of individual SSTR sub-
types in this context.
 In a previous study, modulation of the IGF2/IGF1R 
autocrine loop was demonstrated in BON-1 cells using 
neutralizing IGF2 antibodies  [27] . To assess the IGF2-
mediated activity of IR-A, we used an IR-A KIRA bioas-
say developed in-house. In the current study, we focused 
on IR-A bioactivity, as stimulation of IR-A by IGF2 may 
play a role in signal transduction in tumorigenesis  [7, 9] . 
With the IR-A bioassay, we found that stimulation of the 
phosphorylation of tyrosine residues of IR-A by condi-
tioned medium of BON-1 cells was as potent as stimula-
tion with 167 p M recombinant human insulin. As indi-
cated above, a significant IR-A bioactivity of conditioned 
medium of QGP-1 cells was not observed. This may be 
explained by the reduced IGF2 mRNA expression in 
QGP-1 cells, which was approximately 1,000-fold lower 
than in BON-1 cells.
 Since BON-1 cells only produce IGF2 but not IGF1, 
the most likely explanation for the observed IR-A activa-
tion in BON-1 cells is the production of IGF2. After 72 h 
of incubation, BON-1 cells treated with PAS + CAB 
showed a significant decrease in IGF2 mRNA, while no 
HE IGF2 Negative control
IR
S 
6
IR
S 
4
IR
S 
2
a b c
d e f
g h i
 Fig. 6. Exemplary cases of IGF2 IRSs of GEP-NET tissues.  a–f siNETs (n = 18).  g–i panNETs (n = 7).  a ,  d ,  g HE. 
 b ,  e ,  h IGF2.  c ,  f ,  i Negative controls. 
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effects were observed on mRNA expression after incuba-
tion with any of the other components. PAS and CAB 
monotherapy had less effect on mRNA expression. There 
was only a borderline reduction in IGF2 mRNA after 
treatment with BIM-23A760. Although SSTR1 was the 
most highly expressed SSTR subtype in our BON-1 cell 
line, a 72-hour incubation of BON-1 cells with BIM-
23926 (SSTR1 analog) did not result in a statistically sig-
nificant change in IGF2 mRNA expression compared to 
untreated BON-1 cells (+113.80 ± 19.31%, p = 0.52) [un-
publ. data]. Apparently, targeting SSTR1 is not effective 
in modulating IGF2 mRNA levels. Overall, these results 
suggest that the SSTR subtypes 2 and 5 and D2Rs may 
play a role in modulating IGF2 mRNA levels.
 BIM-23A760 treatment resulted in a significant de-
crease in secreted IGF2, while no effect was seen after any 
of the other treatments. Treatment with PAS + CAB or 
BIM-23A760 induced a significant decrease in IR-A bio-
activity. In the IR-A KIRA bioassay, all compounds or 
combinations, except OCT, were able to suppress the ac-
tivation of IR-A. This result indicates that BON-1 condi-
tioned medium-induced IR-A activation can be modified 
by the (combined) activation of D2R and SSTR subtypes 
2 and 5. The absence of an effect of OCT may be explained 
by the very low SSTR2 expression in BON-1 cells.
 While IGF2 expression has previously been demon-
strated in GEP-NET tissue at the mRNA level, there are 
no large studies that have evaluated IGF2 protein expres-
sion. In order to study whether IGF2 is also highly ex-
pressed in GEP-NET tissues, we performed IHC. The 
GEP-NET tumors also expressed IGF2 protein at a sig-
nificant but variable level. Protein expression of SSTRs 
has already previously been examined in GEP-NET cells 
 [46] . No significant correlations were observed by IHC 
between IGF2 mRNA expression and IGF2 protein posi-
tivity in GEP-NET tissues. Nonetheless, our study sug-
gests that IGF2 is expressed at significant levels in almost 
all GEP-NETs. No significant association between IGF2 
IRS and Ki-67 index was found as well, which may be ex-
plained by the small sample size of our GEP-NET series.
 Although the BON-1 and QGP-1 cell lines are both 
originating from panNETs, discrepancies in results of
experiments between the panNET cell lines indicate
that these cell lines represent two different tumor sub-
types, namely tumors with a low IGF2 production and 
panNETs with high levels of IGF2 secretion.
 In conclusion, the human BON-1 panNET cell line, 
and to a lesser extent the QGP-1 cell line, appears to be a 
suitable model for studying the role of the IGF system in 
human panNETs. Of all the IGF-related factors, IGF2 and 
IR-A seem the most important players in human BON-1 
panNET cells and human GEP-NETs. We found that 
most GEP-NET tissues express IGF2 protein as well. In 
our hands, therapies with the combination of PAS + CAB 
or with the SS-DA chimeric compound BIM-23A760, 
which act through D2R and SSTR subtypes 2 and 5, 
showed especially inhibitory effects on autocrine/para-
crine (IGF2)-induced IR-A activation. Our study sug-
gests that combinations of SSAs and DAs and/or chimeric 
SS-DA ligands are treatment options showing promise 
for the treatment of GEP-NETs, and they should be in the 
focus of future research.
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